Articles from Agilent Technologies Inc.

Agilent Technologies Inc. (NYSEA) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST.

Agilent Technologies Inc. (NYSEA) announced today that it will feature new automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition being held January 25-29, at the San Diego Convention Center in California. Agilent is a leader in advancing automation solutions to help customers optimize lab performance, efficiency, and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes.

Agilent Technologies Inc. (NYSEA) today announced Solutions Innovation Research Awards (SIRA) have been presented to Professor Anders Bentien of Aarhus University, Professor Walter Gössler of University of Graz, and Professor Gregory Offer of Imperial College London. These separate awards recognize their outstanding contributions to battery research.

Agilent Technologies Inc. (NYSEA) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14, 2025, at 9:45 a.m. Pacific time.

Agilent Technologies Inc. (NYSEA) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR) 1. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution.

Agilent Technologies Inc. (NYSEA) today reported revenue of $1.70 billion for the fourth quarter ended October 31, 2024, an increase of 0.8% reported and a decline of 0.3% core(1) compared to the fourth quarter of 2023.

Agilent Technologies Inc. (NYSEA) today announced a new organizational structure to accelerate the company’s operational transformation to drive higher growth through a market-focused, customer-centric enterprise strategy. The new structure, including new leadership roles, takes effect immediately.

Agilent Technologies, Inc. (NYSEA) today announced the company has increased its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 22, 2025, to all shareholders of record as of the close of business on Dec. 31, 2024.

Agilent Technologies Inc. (NYSEA) announced today that Adeyemi Adeleye, Ph.D., has received the Agilent 2024 Early Career Professor Award for his contribution to environmental health and sustainability, developing green analytical technologies, methods, or laboratory working environments. Dr. Adeleye is an assistant professor in the Department of Earth and Environmental Engineering at Columbia University.

Agilent Technologies Inc. (NYSEA) today announced the company has been named to Fortune’s list of Best Workplaces in the World, ranking no. 11 among 25 companies.

Agilent Technologies Inc. (NYSEA) announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated analysis of mitochondrial function available to researchers of all skill levels. With this cost-effective and versatile kit, researchers can easily incorporate functional assessment of relative mitochondrial respiration into their cell physiology and disease pathology studies.

Agilent Technologies Inc. (NYSEA) today announced that Professor Isabelle Plante at Institut National de la Recherche Scientifique (INRS), and Professor Bangyan Stiles at the University of Southern California (USC) are recipients of an Agilent Solutions Innovation Research Award (SIRA). The honorees will receive separate awards on behalf of their institutions in recognition of their research in cell and gene therapy.

Agilent Technologies Inc. (NYSEA) today announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions. These are the first HPLC systems on the market to feature the new Agilent InfinityLab Assist Technology, offering enhanced, built-in system assistance capabilities. This technology allows labs to focus more on achieving results rather than on daily operation and maintenance tasks.

Agilent Technologies Inc. (NYSEA) will release financial results for the fourth quarter of fiscal year 2024 after the stock market closes on Monday, Nov. 25. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST.

Agilent Technologies Inc. (NYSEA) will host an Analyst and Investor Day in New York City on Tuesday, Dec. 17, at 10 a.m. ET.

Agilent Technologies Inc. (NYSEA) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

Agilent Technologies, Inc. (NYSEA) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024.

Agilent Technologies Inc., (NYSEA) today announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, following receipt of California State clinical laboratory license and Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance.

Agilent Technologies Inc. (NYSEA) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core(1) compared to the third quarter of 2023.

Agilent Technologies Inc., (NYSEA) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column technology. Agilent has a 50-year history of innovation in gas chromatography, continually setting the standard for GC column performance. The new Agilent J&W 5Q GC/MS columns combine Agilent’s industry-recognized ultra-inert performance and ultra-low-bleed technology, delivering unmatched performance and durability for the most demanding applications.

Agilent Technologies Inc., (NYSEA) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovial sarcoma who may be eligible for treatment with TECELRA® (afamitresgene autoleucel, also known as afami-cel or ADP-A2M4), a MAGE-A4-directed engineered TCR T-Cell therapy.

Agilent Technologies Inc. (NYSEA) today announced it has acquired Sigsense Technologies, a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help optimize lab operations. Financial terms of the acquisition were not disclosed.

Agilent Technologies Inc. (NYSEA) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million.

Agilent Technologies Inc. (NYSEA) will release financial results for the third quarter of fiscal year 2024 after the stock market closes on Aug. 21. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT.

Agilent Technologies, Inc. (NYSEA) today announced Bret DiMarco has been named to lead the company’s global legal organization as senior vice president and chief legal officer, as well as serving as secretary. He begins his new role with Agilent effective today.

Agilent Technologies Inc. (NYSEA) today released the company’s annual ESG report, showcasing a comprehensive and growing set of sustainable solutions that enable hundreds of thousands of labs worldwide to reduce consumption of nonrenewable resources and to minimize waste.

Agilent Technologies Inc., (NYSEA) is introducing two new products at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics. The Agilent 7010D Triple Quadrupole GC/MS System which targets the food and environmental markets, offers precision and sensitivity in gas chromatography-mass spectrometry. Additionally, the Agilent ExD Cell for use with the 6545XT AdvanceBio LC/Q-TOF system, serves the biopharma market and life science research. These instruments exemplify Agilent’s unwavering commitment to advancing scientific discovery through innovative instrumentation, significantly shaping the landscape of mass spectrometry.

Agilent Technologies Inc. (NYSEA) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core(1) compared to the second quarter of 2023.

Agilent Technologies Inc. (NYSEA) today announced that Hans E. Bishop, president and co-founder of Altos Labs, has stepped down from serving on Agilent’s board of directors.

Agilent Technologies Inc., (NYSEA) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals, while reducing energy consumption by up to 30%.

Agilent Technologies, Inc. (NYSEA) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on July 24, 2024, to all shareholders of record as of the close of business on July 2, 2024.

Agilent Technologies Inc., (NYSEA) will showcase its latest mass spectrometry innovations at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, scheduled for June 2 - 6, 2024, in Anaheim, California. A global leader in analytical instruments, Agilent continues to drive performance and accessibility in mass spectrometry.

Agilent Technologies Inc. (NYSEA) today announced that CFO Bob McMahon will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 5, at 8:30 a.m. EDT.

Agilent Technologies Inc. (NYSEA) today announced two Solutions Innovation Research Awards (SIRA) presented to Professors Richard Robinson of Cornell University and Xingchen Ye of Indiana University. These separate awards recognize their outstanding contributions to advanced materials research.

Agilent Technologies Inc. (NYSEA) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PT.

Agilent Technologies Inc. (NYSEA) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31.

Agilent Technologies Inc. (NYSEA) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development.

Agilent Technologies, Inc. (NYSEA) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6.

Agilent Technologies Inc. (NYSEA) announces that it is the recipient of two 2023 Sustainability Scientists’ Choice awards — Sustainable Supplier of the Year and Sustainable Product of the Year. These awards recognize Agilent as a leader in the area of sustainability.

Agilent Technologies Inc. (NYSEA) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the higher standards established by IVDR. It ensures the continued availability of this trusted qualitative assay to clinical geneticists and other healthcare professionals throughout the EU.

Agilent Technologies Inc. (NYSEA) today announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows. Analytica, the premier international trade fair for laboratory technology, analysis, and biotechnology, is scheduled to take place from April 9 to 12 in Munich, Germany.

Agilent Technologies Inc. (NYSEA), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR). At the meeting, which will take place from April 5 to 10, 2024, in San Diego, CA, Agilent will highlight new cell analysis, genomics, digital pathology, and companion diagnostics solutions.

Agilent Technologies Inc. (NYSEA), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked public research universities in the world, today announced an innovative scientific collaboration to establish the Agilent Center of Excellence (CoE) in Cellular Intelligence.

Agilent Technologies Inc. (NYSEA) today announced the launch of the Advanced Dilution System, the ADS 2, a new automation workflow solution that will increase productivity, lower cost of ownership, and improve the overall efficiency within the laboratory.

Agilent Technologies Inc. (NYSEA) announced today that Joycelyn Tan, a Ph.D. student at the Wellcome-MRC Institute of Metabolic Science at the University of Cambridge, UK, has been awarded the 2024 Darlene Solomon Award. The award recognizes and supports promising female scientists working in mass spectrometry.

Agilent Technologies Inc. (NYSEA) today announced the selection of Distinguished Professors Michel Barsoum and Yury Gogotsi at Drexel University and Professor Ananda Amarasekara at Prairie View A&M University as recipients of an Agilent Solutions Innovation Research Award (SIRA). The three honorees will receive separate awards for their research into materials to advance energy storage technology.

Agilent Technologies Inc. (NYSEA) today reported revenue of $1.66 billion for the first quarter ended Jan. 31, 2024, a decline of 5.6% reported and 6.4% core(1) compared to the first quarter of 2023.

Agilent Technologies Inc. (NYSEA) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on April 24, 2024, to all shareholders of record as of the close of business on April 2, 2024.

Agilent Technologies Inc. (NYSEA) today announced that Padraig McDonnell, president of the Agilent CrossLab Group (ACG), has been named CEO-elect and chief operating officer (COO) of the company, succeeding current President and CEO Mike McMullen who will retire. McDonnell will become Agilent’s president and CEO and join Agilent’s Board of Directors on May 1.

Agilent Technologies Inc. (NYSEA) today announced the company was again named one of the Most JUST Companies in America by Just Capital and CNBC. This marks the sixth year Agilent has appeared on the exclusive list, and the fourth year the company has ranked in the top 50.

Agilent Technologies Inc. (NYSEA) announced today that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year. These accolades highlight Agilent’s commitment to innovation and excellence in drug discovery and development.

Agilent Technologies Inc. (NYSEA) today announced that CFO Bob McMahon will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference in Boston, Massachusetts, on Monday, March 4, at 2:50 p.m. EST.

Agilent Technologies Inc. (NYSEA) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio.

Agilent Technologies Inc. (NYSEA) will release financial results for the first quarter of fiscal year 2024 after the stock market closes on Tuesday, Feb. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST.

Agilent Technologies Inc. (NYSEA) today announced the release of a new automated parallel capillary electrophoresis system for protein analysis – the Agilent ProteoAnalyzer system – at the 23rd Annual PepTalk Conference, being held January 16-19 in San Diego. This new platform simplifies and improves the efficiency of analyzing complex protein mixtures, a process central to analytical workflows across the pharma, biotech, food analysis, and academia sectors.

Agilent Technologies Inc. (NYSEA) today announced the company has again been included in the Dow Jones Sustainability World Index and the North America Index for its strong environmental, social, and governance (ESG) performance.

Agilent Technologies Inc. (NYSEA) today announced it has moved the company’s Cell Analysis Division into its Diagnostics and Genomics Group (DGG) as part of a strategy to further strengthen growth opportunities for both organizations.

Agilent Technologies Inc. (NYSEA) today announced that CEO Mike McMullen and CFO Bob McMahon will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 9, 2024, at 9:45 a.m. Pacific Time.

Agilent Technologies Inc. (NYSEA) today announced the company’s manufacturing facility in Waldbronn, Germany, has been named a Global Lighthouse by the World Economic Forum (WEF) for innovations that boost productivity, output, and quality.

Agilent Technologies Inc. (NYSEA) today announced that the Agilent Resolve Handheld Raman Spectrometer has been recognized for excellence as a tool for emergency responders following independent use and evaluation by both the UK’s National CBRN Centre, and the US’ Department of Homeland Security.

Agilent Technologies Inc. (NYSEA) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features improve image quality and results by reducing deleterious effects on live-cell samples and enhancing clarity for thicker samples such as tissues and 3-D spheroids.

Agilent Technologies Inc. (NYSEA) today reported revenue of $1.69 billion for the fourth quarter ended Oct. 31, 2023, a decline of 8.7% reported and 9.7% core(1) compared to the fourth quarter of 2022.

Agilent Technologies Inc. (NYSEA) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 6th Annual Evercore ISI HealthCONx conference on Wednesday, Nov. 29, at 10:50 a.m. ET.

Agilent Technologies Inc. (NYSEA) today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 24, 2024, to all shareholders of record as of the close of business on Jan. 2, 2024.

Agilent Technologies Inc. (NYSEA) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Agilent Technologies Inc. (NYSEA) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader Award. A professor in the Environmental and Molecular Toxicology Department at Oregon State University’s College of Agricultural Sciences, Dr. Field focuses her research on the quantitative analysis of organic micropollutants and their transformation products in natural and engineered systems, particularly per- and polyfluoroalkyl substances (PFAS).

Agilent Technologies Inc. (NYSEA) will release financial results for the fourth quarter of fiscal year 2023 after the stock market closes on Monday, Nov. 20. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST.

Agilent Technologies Inc. (NYSEA) today announced the company’s near and long-term targets for reaching net-zero greenhouse gas emissions have been approved by the Science Based Targets initiative (SBTi). The targets support the ambitious goal to limit planetary warming to 1.5°C above pre-industrial levels.

Agilent Technologies, Inc. (NYSEA) today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on Oct. 25, 2023, to all shareholders of record as of the close of business on Oct. 3, 2023.

Agilent Technologies, Inc. (NYSEA) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.

Agilent Technologies, Inc. (NYSEA) today announced Philip Binns has been named president of the company’s Life Sciences and Applied Markets Group (LSAG). Binns previously served as vice president and general manager of the Spectroscopy and Vacuum Solutions Division for LSAG. Binns replaces Jacob Thaysen who left the company effective today.

Agilent Technologies Inc. (NYSEA) today announced the issuing of a companion diagnostic (CDx) Class C IVDR certification for PD-L1 IHC 22C3 pharmDx, Code SK006. This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR).

Agilent Technologies Inc. (NYSEA) today reported revenue of $1.67 billion for the third quarter ended July 31, 2023, a decrease of 2.7% compared to the third quarter of 2022 and a decrease of 2.3% on a core(1) basis.

Agilent Technologies Inc. (NYSEA) announced today that Ajit Divakaruni, Ph.D., has received the Agilent 2023 Early Career Professor Award. Dr. Divakaruni is an Assistant Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA).

Agilent Technologies Inc. (NYSEA) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical University of Berlin, Dr. Neubauer leads innovative research to identify new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications.